Xianling Liu
Overview
Explore the profile of Xianling Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
917
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hu X, Zhong P, Liu C, Liu X, Xie J, Hu C
Exp Ther Med
. 2025 Mar;
29(4):79.
PMID: 40084197
Neoadjuvant chemoimmunotherapy (NCIO) is a new and effective treatment for cancer, but its efficacy in treating certain patients is unclear. We previously found that comorbidity was an independent factor associated...
2.
Lin J, Qu S, Yang K, Zhang T, Bai Y, Wu J, et al.
Cancer Lett
. 2025 Feb;
613:217513.
PMID: 39892704
Treatment options for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) are limited, especially for patients who progress after immune checkpoint inhibitor (ICI) therapy. This phase Ib...
3.
Liu X, Chu A, Ding X
Front Nutr
. 2024 Dec;
11:1481155.
PMID: 39659906
Background: The prognostic value of the uric acid to albumin ratio (UAR) in heart failure (HF) remains underexplored. The objective of this research was to investigate the link between UAR...
4.
Zhao Y, Xiong S, Ren Q, Wang J, Li M, Yang L, et al.
Lancet Oncol
. 2024 Dec;
26(1):136-146.
PMID: 39653054
Background: Accurate detection of driver gene mutations is crucial for treatment planning and predicting prognosis for patients with lung cancer. Conventional genomic testing requires high-quality tissue samples and is time-consuming...
5.
Chen Z, Wu L, Wang Q, Yu Y, Liu X, Ma R, et al.
J Thorac Oncol
. 2024 Nov;
20(2):233-239.
PMID: 39490738
Introduction: Ivonescimab is a humanized IgG1 bispecific anti-programmed cell death protein 1/vascular endothelial growth factor antibody. This study aimed to evaluate the safety and tolerance of ivonescimab combined with etoposide...
6.
Wu X, Sun Y, Yang H, Wang J, Lou H, Li D, et al.
Lancet
. 2024 Oct;
404(10463):1668-1676.
PMID: 39426385
Background: Cadonilimab is a bispecific antibody targeting PD-1 and CTLA-4, which has shown substantial clinical benefits in advanced cervical cancer. In the COMPASSION-16 trial, we aimed to evaluate the addition...
7.
Fang W, Zhao Y, Luo Y, Yang R, Huang Y, He Z, et al.
JAMA
. 2024 May;
332(7):561-570.
PMID: 38820549
Importance: For patients with non-small cell lung cancer whose disease progressed while receiving EGFR tyrosine kinase inhibitor (EGFR-TKI) therapy, particularly third-generation TKIs, optimal treatment options remain limited. Objective: To compare...
8.
Li Y, Chen K, Chen B, Zeng R, He Y, Wang C, et al.
Leukemia
. 2024 May;
38(7):1553-1563.
PMID: 38783159
Immunotherapy with programmed cell death 1 ligand 1 (PD-L1) blockade was effective in patients with NK/T-cell lymphoma. In addition to PD-L1, indoleamine 2,3-dioxygenase-1 (IDO1) is one of the most promising...
9.
Guo Y, Liu X, Tang H, Qiu Z, Ma F, Hu A, et al.
Front Immunol
. 2024 Apr;
15:1374270.
PMID: 38650938
Pulmonary sarcomatoid carcinoma (PSC) represents a rare and highly aggressive variant of lung cancer, characterized by its recalcitrance to conventional therapeutic modalities and the attendant dismal prognosis it confers. Recent...
10.
Chen Z, Ling J, Zhang S, Feng Y, Xie Y, Liu X, et al.
Head Neck
. 2024 Apr;
46(10):2600-2615.
PMID: 38646952
Background: Serum biomarkers have a significant impact on the prediction of treatment outcomes in patients diagnosed with nasopharyngeal carcinoma (NPC). The primary aim of this study was to develop and...